Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage i lung cancer or small lung metastasis

Radiotherapy and Oncology

Volumn 101, Issue 2, 2011, Pages 267-270

  Iwata, Hiromitsu ^a   Shibamoto, Yuta ^a   Baba, Fumiya ^a   Sugie, Chikao ^a   Ogino, Hiroyuki ^a   Murata, Rumi ^a   Yanagi, Takeshi ^a   Otsuka, Shinya ^a   Kosaki, Katsura ^a   Murai, Taro ^a   Miyakawa, Akifumi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

KL 6; Lung tumor; Radiation pneumonitis; Stereotactic body radiotherapy

Indexed keywords

CARBOHYDRATE ANTIGEN; CARBOHYDRATE ANTIGEN KL 6; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; OXYGEN BREATHING; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIATION PNEUMONIA; RADIATION RESPONSE; RADIATION SAFETY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIATION PNEUMONITIS; RADIOSURGERY; RADIOTHERAPY DOSAGE; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 81755179416     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.05.031     Document Type: Article

References (22)

1. C.L. Ong, W.F. Verbakel, J.P. Cuijpers, B.J. Slotman, F.J. Lagerwaard, and S. Senan Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques Radiother Oncol 97 2010 437 442
2. S.K. Nath, A.P. Sandhu, and D. Kim Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer Radiother Oncol 99 2011 12 17
3. H. Jin, S.L. Tucker, and H.H. Liu Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy Radiother Oncol 91 2009 427 432
4. M. Guckenberger, K. Baier, and B. Polat Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy Radiother Oncol 97 2010 65 70
5. N. Kohno, M. Akiyama, and S. Kyoizumi Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma Jpn J Clin Oncol 18 1988 203 216
6. R.A. Stahel, W.R. Gilks, and H.-P. Lehmann Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis Int J Cancer Suppl 8 1994 6 26 (Pubitemid 24188951)
7. J. Hilkens, M.J. Ligtenberg, and H.L. Vos Cell membrane-associated mucins and their adhesion-modulating property Trends Biochem Sci 17 1992 359 363
8. N. Kohno, S. Kyoizumi, and Y. Awaya New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6 Chest 96 1989 68 73 (Pubitemid 19176416)
9. K. Goto, T. Kodama, and I. Sekine Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis Lung Cancer 34 2001 141 148 (Pubitemid 32824134)
10. Y. Matsuno, H. Satoh, and H. Ishikawa Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy Med Oncol 23 2006 75 82
11. R. Hara, J. Itami, and T. Komiyama Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors Chest 125 2004 340 344 (Pubitemid 38114606)
12. H. Yamashita, S. Kobayashi-Shibata, and A. Terahara Prescreening based on the presence of CT-scan abnormalities, biomarkers (KL-6, SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy Radiat Oncol 5 2010 32
13. F. Baba, Y. Shibamoto, and N. Tomita Stereotactic body radiotherapy for stage I lung cancer, small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement, preliminary results Radiat Oncol 4 2009 15
14. F. Baba, Y. Shibamoto, and H. Ogino Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size Radiat Oncol 5 2010 81
15. C.E. Metz Basic principles of ROC analysis Semin Nucl Med 8 1978 283 298 (Pubitemid 9075026)
16. P. Rubin, J. Finkelstein, and D. Shapiro Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast Int J Radiat Oncol Biol Phys 24 1992 93 101
17. H. Ohnishi, A. Yokoyama, and K. Kondo Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases Am J Respir Crit Care Med 165 2002 378 381 (Pubitemid 34118512)
18. N. Kohno, H. Hamada, and S. Fujioka Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer Chest 102 1992 117 122
19. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
20. Y. Nagata, M. Hiraoka, and T. Shibata A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan clinical oncology group (JCOG0403) Int J Radiat Oncol Biol Phys 78 2010 S27 S28
21. T. Makimoto, S. Tsuchiya, K. Hayakawa, R. Saitoh, and M. Mori Risk factors for severe radiation pneumonitis in lung cancer Jpn J Clin Oncol 29 1999 192 197
22. N. Kohno Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis J Med Invest 46 1999 151 158 (Pubitemid 129622186)